NYSE:BMY

Bristol-Myers Squibb - BMY Stock Forecast, Price & News

$80.88

+0.60 (+0.75%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $80.05
▼
$81.44
50-Day Range: $68.48
▼
$80.28
52-Week Range: $54.67
▼
$81.43

Volume: 10.29 million shs
Average Volume: 12.33 million shs
Market Capitalization: $171.96 billion

P/E Ratio: 26.35
Dividend Yield: 2.69%
Price Target: $79.00

Bristol-Myers Squibb MarketRank™ Forecast

Analyst Rating: Hold
2.38 Rating Score
Upside/Downside: 2.3% Downside
$79.00 Price Target
Short Interest: Healthy
1.15% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.30
Upright™ Environmental Score
News Sentiment: 0.87
Based on 15 Articles This Week
Insider Trading: Selling Shares
$21.58 M Sold Last Quarter
Proj. Earnings Growth: 3.82%
From $7.60 to $7.89 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.77 out of 5 stars

Medical Sector

73rd out of 1,047 stocks

Pharmaceutical Preparations Industry

32nd out of 512 stocks

2.2

Analyst's Opinion

Consensus Rating
Bristol-Myers Squibb has received a consensus rating of Hold. The company's average rating score is 2.38, and is based on 6 buy ratings, 6 hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $79.00, Bristol-Myers Squibb has a forecasted downside of 2.3% from its current price of $80.88.
Amount of Analyst Coverage
Bristol-Myers Squibb has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

4.0

Short Interest

Percentage of Shares Shorted
1.15% of the float of Bristol-Myers Squibb has been sold short.
Short Interest Ratio / Days to Cover
Bristol-Myers Squibb has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bristol-Myers Squibb has recently decreased by 1.66%, indicating that investor sentiment is improving.

4.2

Dividend Strength

Dividend Yield
Bristol-Myers Squibb pays a meaningful dividend of 2.69%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Bristol-Myers Squibb has been increasing its dividend for 15 years.
Dividend Coverage
The dividend payout ratio of Bristol-Myers Squibb is 70.36%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 27.38% next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.

4.0

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Bristol-Myers Squibb has received a 56.86% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Apixaban", "Lenalidomide", and "Nivolumab" products. See details.
Environmental Sustainability
The Environmental Impact score for Bristol-Myers Squibb is -2.30.

2.7

News and Social Media Coverage

News Sentiment
Bristol-Myers Squibb has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 15 news articles for Bristol-Myers Squibb this week, compared to 16 articles on an average week.
Search Interest
Only 55 people have searched for BMY on MarketBeat in the last 30 days. This is a decrease of -4% compared to the previous 30 days.
MarketBeat Follows
32 people have added Bristol-Myers Squibb to their MarketBeat watchlist in the last 30 days. This is an increase of 23% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bristol-Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,582,900.00 in company stock.
Percentage Held by Insiders
Only 0.09% of the stock of Bristol-Myers Squibb is held by insiders.
Percentage Held by Institutions
76.54% of the stock of Bristol-Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Bristol-Myers Squibb are expected to grow by 3.82% in the coming year, from $7.60 to $7.89 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bristol-Myers Squibb is 26.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.35.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bristol-Myers Squibb is 26.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 152.46.
Price to Earnings Growth Ratio
Bristol-Myers Squibb has a PEG Ratio of 1.87. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bristol-Myers Squibb has a P/B Ratio of 5.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bristol-Myers Squibb (NYSE:BMY) Stock

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Receive BMY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bristol-Myers Squibb and its competitors with MarketBeat's FREE daily newsletter.